PDF   Print   View All
April 20, 2004
Background on New Phase 3 Clinical Data on CFS to be Presented

Philadelphia, PA, Tuesday, April 20, 2004: Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that Dr. William A. Carter, CEO and President, will present at the Second Annual White Mountain Capital Biotechnology Conference. The event takes place Thursday, April 22nd at the Rihga Royal Hotel in New York City and the presentation is scheduled for 2:40 p.m. EST.
Dr. Carter will provide an overview of commercial progress with Alferon N Injection®, a natural source Alpha Interferon, and clinical progress with the Company’s experimental immunotherapeutic Ampligen®. Dr. Carter will also provide an update on 2004 milestones and recent activities that support the expected NDA filing of Ampligen® for the potential treatment of Chronic Fatigue Syndrome (CFS). During the presentation, Dr. Carter will also compare the study design of the successful AMP 502 CFS study (available at the Company’s website) with the current AMP 516 phase 3 study, including patient demographics, duration, dosage and clinical endpoints.

About White Mountain Capital

White Mountain Capital is a full-service investment firm serving individuals, corporations and institutions. In addition to its broker-dealer services, it provides clients with proprietary, independent research on select biotechnology companies.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon N® and the experimental immunotherapeutics/antivirals Ampligen® and Oragens™. These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N®) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net.

Hemispherx Biopharma, Inc.,
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6369

HEB's Web Site: www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including AmpligenÒ and Oragensä) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic AlferonÒ do not imply that the product will ever be specifically approved commercially for these other treatment indications, including SARS.